Abstract
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo. The effect sizes were mean differences and odds ratio (ORs) with 95% confidence intervals (CIs) for the primary efficacy endpoint and safety/tolerability between two LAIAs, respectively. Mean difference in the primary efficacy endpoint was significantly different, favouring AOM over PP (OR:-6.4; 95% CI:-11.402 to-1.358); sensitivity analyses and noninferiority test (AOM vs. PP) confirmed the primary results. The overall early dropout rate was not significantly different between AOM and PP (OR: 1.223; 95% CI: 0.737-2.03). However, there was a significant difference in the early dropout rate in terms of lack of efficacy favouring AOM over PP (OR: 0.394; 95% CI: 0.185-0.841). Within the context of the inherent limitations of the current analysis, our results may suggest that there may be relative advantages for AOM over PP in the short-term treatment of schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 235-248 |
| Number of pages | 14 |
| Journal | International Clinical Psychopharmacology |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2017 Jan 1 |
Fingerprint
Keywords
- Aripiprazole once monthly
- Efficacy
- Indirect comparison
- Paliperidone palmitate
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia : Systematic review and indirect treatment comparison. / Pae, Chi Un; Wang, Sheng Min; Han, Changsu; Bahk, Won Myong; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.; Serretti, Alessandro; Emsley, Robin.
In: International Clinical Psychopharmacology, Vol. 32, No. 5, 01.01.2017, p. 235-248.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia
T2 - Systematic review and indirect treatment comparison
AU - Pae, Chi Un
AU - Wang, Sheng Min
AU - Han, Changsu
AU - Bahk, Won Myong
AU - Lee, Soo Jung
AU - Patkar, Ashwin A.
AU - Masand, Prakash S.
AU - Serretti, Alessandro
AU - Emsley, Robin
PY - 2017/1/1
Y1 - 2017/1/1
N2 - We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo. The effect sizes were mean differences and odds ratio (ORs) with 95% confidence intervals (CIs) for the primary efficacy endpoint and safety/tolerability between two LAIAs, respectively. Mean difference in the primary efficacy endpoint was significantly different, favouring AOM over PP (OR:-6.4; 95% CI:-11.402 to-1.358); sensitivity analyses and noninferiority test (AOM vs. PP) confirmed the primary results. The overall early dropout rate was not significantly different between AOM and PP (OR: 1.223; 95% CI: 0.737-2.03). However, there was a significant difference in the early dropout rate in terms of lack of efficacy favouring AOM over PP (OR: 0.394; 95% CI: 0.185-0.841). Within the context of the inherent limitations of the current analysis, our results may suggest that there may be relative advantages for AOM over PP in the short-term treatment of schizophrenia.
AB - We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo. The effect sizes were mean differences and odds ratio (ORs) with 95% confidence intervals (CIs) for the primary efficacy endpoint and safety/tolerability between two LAIAs, respectively. Mean difference in the primary efficacy endpoint was significantly different, favouring AOM over PP (OR:-6.4; 95% CI:-11.402 to-1.358); sensitivity analyses and noninferiority test (AOM vs. PP) confirmed the primary results. The overall early dropout rate was not significantly different between AOM and PP (OR: 1.223; 95% CI: 0.737-2.03). However, there was a significant difference in the early dropout rate in terms of lack of efficacy favouring AOM over PP (OR: 0.394; 95% CI: 0.185-0.841). Within the context of the inherent limitations of the current analysis, our results may suggest that there may be relative advantages for AOM over PP in the short-term treatment of schizophrenia.
KW - Aripiprazole once monthly
KW - Efficacy
KW - Indirect comparison
KW - Paliperidone palmitate
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85018812240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018812240&partnerID=8YFLogxK
U2 - 10.1097/YIC.0000000000000177
DO - 10.1097/YIC.0000000000000177
M3 - Review article
C2 - 28430670
AN - SCOPUS:85018812240
VL - 32
SP - 235
EP - 248
JO - International Clinical Psychopharmacology
JF - International Clinical Psychopharmacology
SN - 0268-1315
IS - 5
ER -